DK1516629T3 - Humaniseret anti-CD-11a antibodies - Google Patents

Humaniseret anti-CD-11a antibodies

Info

Publication number
DK1516629T3
DK1516629T3 DK04004941.3T DK04004941T DK1516629T3 DK 1516629 T3 DK1516629 T3 DK 1516629T3 DK 04004941 T DK04004941 T DK 04004941T DK 1516629 T3 DK1516629 T3 DK 1516629T3
Authority
DK
Denmark
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
DK04004941.3T
Other languages
Danish (da)
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1516629T3 publication Critical patent/DK1516629T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04004941.3T 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies DK1516629T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
EP97912841A EP0941344B1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES

Publications (1)

Publication Number Publication Date
DK1516629T3 true DK1516629T3 (da) 2013-06-03

Family

ID=25046834

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04004941.3T DK1516629T3 (da) 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies
DK97912841T DK0941344T3 (da) 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97912841T DK0941344T3 (da) 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer

Country Status (17)

Country Link
EP (2) EP1516629B1 (cg-RX-API-DMAC7.html)
JP (2) JP3778945B2 (cg-RX-API-DMAC7.html)
KR (1) KR100532178B1 (cg-RX-API-DMAC7.html)
AR (1) AR008919A1 (cg-RX-API-DMAC7.html)
AT (1) ATE267257T1 (cg-RX-API-DMAC7.html)
AU (1) AU731817C (cg-RX-API-DMAC7.html)
CA (1) CA2272842C (cg-RX-API-DMAC7.html)
DE (3) DE122004000047I2 (cg-RX-API-DMAC7.html)
DK (2) DK1516629T3 (cg-RX-API-DMAC7.html)
ES (1) ES2221045T3 (cg-RX-API-DMAC7.html)
FR (1) FR04C0028I2 (cg-RX-API-DMAC7.html)
IL (3) IL130143A0 (cg-RX-API-DMAC7.html)
LU (1) LU91122I2 (cg-RX-API-DMAC7.html)
NL (1) NL300163I2 (cg-RX-API-DMAC7.html)
PT (1) PT941344E (cg-RX-API-DMAC7.html)
WO (1) WO1998023761A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA979599B (cg-RX-API-DMAC7.html)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
CA2367025A1 (en) * 1999-03-19 2000-09-28 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
CN1409639A (zh) * 1999-12-14 2003-04-09 杰南技术公司 应用TNF－α拮抗剂和LFA－1拮抗剂治疗LFA－1或TNF－α介导的疾病
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
WO2002018583A2 (en) * 2000-09-01 2002-03-07 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
EP2048154B2 (en) 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
CA2523142A1 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
AU2005215024B2 (en) * 2004-02-19 2011-07-21 Dyax Corp. Conformation specific antibodies
CA2568570A1 (en) * 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
EP2377527B1 (en) 2007-01-22 2013-07-17 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
CA3113365A1 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
ES2758126T3 (es) * 2008-04-09 2020-05-04 Genentech Inc Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
HUE047316T2 (hu) 2008-08-14 2020-04-28 Genentech Inc Eljárások szennyezés eltávolítására indigén fehérjekiszorításos ioncserés membrán kromatográfia alkalmazásával
EP2334323A2 (en) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
CN105037535A (zh) 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
CN104726394B (zh) 2009-11-12 2018-12-18 VCell治疗股份有限公司 类孢子细胞子群及其用途
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CN103124564B (zh) 2010-03-22 2016-11-09 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
ES2751381T3 (es) 2010-06-24 2020-03-31 Hoffmann La Roche Composiciones y procedimientos que contienen alquilglucósidos para estabilizar formulaciones que contienen proteínas
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
MY171729A (en) 2012-03-27 2019-10-25 Genentech Inc Improved harvest operations for recombinant proteins
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
BR112016000106B1 (pt) 2013-07-09 2023-11-21 Annexon, Inc. Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados
MX384142B (es) 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
SI3166401T1 (sl) 2014-07-09 2020-11-30 F. Hoffmann-La Roche Ag Prilagoditev pH-vrednosti za okrevanje celičnih bank po odtajanju
KR102626877B1 (ko) 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 인간화 항-보체 인자 c1q 항체 및 이의 용도
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
CR20220186A (es) 2015-09-25 2022-07-07 Genentech Inc ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225)
IL296130A (en) 2015-11-24 2022-11-01 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
US10941406B2 (en) 2016-03-29 2021-03-09 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
MX2020013633A (es) 2018-07-03 2021-03-25 Bristol Myers Squibb Co Metodos para producir proteinas recombinantes.
US12415980B2 (en) 2018-10-10 2025-09-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
KR20220039777A (ko) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
JP2023542924A (ja) 2020-09-22 2023-10-12 ブリストル－マイヤーズ スクイブ カンパニー 治療タンパク質を生産するための方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
DE69729209T2 (de) 2005-05-19
AU731817B2 (en) 2001-04-05
EP1516629B1 (en) 2013-04-03
EP1516629A3 (en) 2006-09-27
EP0941344A1 (en) 1999-09-15
KR100532178B1 (ko) 2005-12-01
NL300163I1 (nl) 2005-01-03
EP0941344B1 (en) 2004-05-19
JP2006036779A (ja) 2006-02-09
JP2001505425A (ja) 2001-04-24
FR04C0028I2 (cg-RX-API-DMAC7.html) 2007-10-26
JP3778945B2 (ja) 2006-05-24
FR04C0028I1 (cg-RX-API-DMAC7.html) 2005-02-11
AU731817C (en) 2001-11-01
NL300163I2 (nl) 2005-07-01
DE122004000047I2 (de) 2006-06-14
EP1516629A2 (en) 2005-03-23
AU4992997A (en) 1998-06-22
IL175583A0 (en) 2006-09-05
JP4309383B2 (ja) 2009-08-05
IL130143A0 (en) 2000-06-01
CA2272842A1 (en) 1998-06-04
DE69729209D1 (de) 2004-06-24
IL130143A (en) 2006-08-01
ATE267257T1 (de) 2004-06-15
AR008919A1 (es) 2000-02-23
DE122004000047I1 (de) 2005-04-21
LU91122I2 (fr) 2005-01-10
WO1998023761A1 (en) 1998-06-04
ZA979599B (en) 1999-04-28
ES2221045T3 (es) 2004-12-16
DK0941344T3 (da) 2004-09-27
KR20000069147A (ko) 2000-11-25
PT941344E (pt) 2004-10-29
CA2272842C (en) 2012-05-15

Similar Documents

Publication Publication Date Title
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
NO955167D0 (no) Monoklonalt anti-
CY2007012I2 (el) Αντισωματα anti-vegf
IL128406A0 (en) Monoclonal antibodies
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
NO985464D0 (no) Konsentrert antistoffpreparat
DK145493D0 (da) Antistof
DE69622451D1 (de) Funktelefon
DK0837927T3 (da) Anti-CD80-antistoffer
FI965032A7 (fi) Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
NO981454L (no) Anti-FAS-antistoffer
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
EP0977590A4 (en) HUMAN MONOCLONAL ANTIBODIES
GB9718911D0 (en) Monoclonal antibodies
NO20011006D0 (no) Høy-affinitets antistoffer
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
KR960029102U (ko) 가족 납골묘
BR9609863A (pt) Fecho
BR1100555B1 (pt) anticorpos monoclonais humanizados.
UA10736A (uk) Ћ†љ
GB9615027D0 (en) Monoclonal antibodies
DK0919617T3 (da) Monoklonale antistoffer mod humant MP52